Arbor cuts early-stage discovery work, lays off staff
Arbor Biotechnologies is trimming its early-stage discovery work, leading to layoffs in the group. The move was confirmed by an Arbor spokesperson, with CEO Devyn Smith saying in a statement to...
View ArticleAdcomm says Intercept's rare liver disease drug should not get full approval
An FDA advisory committee recommended against full approval for Alfasigma and Intercept Pharmaceuticals’ rare liver disease drug Ocaliva by a 13-1 vote, concluding that confirmatory evidence didn’t...
View ArticleSEC probe of Illumina’s Grail deal targets sales forecasts, sources say
The SEC’s investigation into the $8 billion deal between Grail and Illumina is examining sales forecasts made by Grail’s management in the run-up to the 2021 transaction, according to sources familiar...
View ArticleClik here to view.
#ESMO24: GSK, iTeos rejuvenate struggling TIGIT space with positive Phase 2...
BARCELONA — GSK and iTeos have unveiled positive mid-phase data for their PD-1 plus TIGIT doublet in certain lung cancer patients, bolstering expectations for an ongoing Phase 3 trial that is testing...
View ArticleClik here to view.
#ESMO24: Nuvation Bio outlines pooled data for former AnHeart drug in...
Nuvation Bio outlined pooled data from its two Phase 2 studies at the annual European Society for Medical Oncology confab in Barcelona this weekend as it prepares to approach the FDA soon. The company...
View ArticleHouse passes Biosecure Act; Moderna outlines more cost cuts; What's happening...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleClik here to view.
#ESMO24: Bristol Myers touts LAG-3 strategy in lung cancer as it preps for...
BARCELONA — Bristol Myers Squibb’s LAG-3 approach has shown potential in certain lung cancer patients in a Phase 2 study, drawing some reassurance in its planned late-stage trial against Merck’s...
View ArticleClik here to view.
#ESMO24: Pfizer tees up Phase 3 in 2025 in weight management, but in an...
BARCELONA — At a major cancer conference, Pfizer made an unexpected announcement: It has late-stage plans in weight management. But it’s not targeting weight loss like one would first think amid the...
View ArticleClik here to view.
#ESMO24: Incyte gears up to face FDA once again with more Zynyz data in rare...
BARCELONA — Incyte said it has positive late-phase results for its PD-1 drug Zynyz in certain patients with squamous cell carcinoma, three years after the FDA asked for more data. The Phase 3...
View ArticleClik here to view.
#ESMO24: Scorpion details early data that helped it raise $150M for PI3Kɑ...
BARCELONA — In a first test of Scorpion Therapeutics’ therapy for breast cancer and other solid tumors, a small group of patients saw their tumors shrink following treatment with no severe cases of...
View ArticleClik here to view.
#ESMO24: AstraZeneca unveils what it calls ‘practice-changing’ Imfinzi data...
BARCELONA — In a result that’s likely to change how some bladder cancer patients get care, AstraZeneca said that its drug Imfinzi boosted patient survival alongside chemotherapy and surgery. Two years...
View ArticleClik here to view.
#ESMO24: Keytruda and Lenvima still have a hill to climb following latest...
BARCELONA — Merck’s bumpy six-year relationship with Eisai’s anti-cancer medication Lenvima landed on somewhat better footing in Spain over the weekend, but the duo is not out of the clear yet....
View ArticleClik here to view.
#ESMO24: In surprise, study suggests Covid mRNA vaccines may boost cancer...
The mRNA-based Covid vaccines used by hundreds of millions of people may provide an unexpected benefit to some cancer patients, significantly improving survival when given within a few months of...
View ArticleClik here to view.
Biotech IPO market still in flux following flashy Friday tripleheader
Three clinical-stage biotechs, three upsized offerings and three first-day share spikes. Last Friday’s biotech IPO tripleheader was a multiyear rarity for an industry still grasping for a more lively...
View ArticleClik here to view.
#ESMO24: Exelixis’ drug staves off neuroendocrine tumor progression in broad...
BARCELONA — A new treatment option for a wide range of patients diagnosed with neuroendocrine tumors could be approved in April, as final results of a Phase 3 study on Exelixis’ cabozantinib were...
View ArticleClik here to view.
#ESMO24: Merck's Eliav Barr on subcutaneous Keytruda, Summit's data, 'fetch...
BARCELONA — In the span of 30 minutes, 29-year Merck veteran Eliav Barr can analogize drug development dealmaking to Reese’s candy, call himself an “old fart” when asked about career plans, get real...
View ArticlePhysical therapy startup Sword Health shifts to a novel way of getting paid
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) An AI-powered digital physical therapy startup is the latest health tech company to switch to a...
View ArticleImmatics loses Bristol Myers' support on Phase 1 bispecific T cell engager
BARCELONA — Immatics presented more clinical data on its bispecific T cell engager at Europe’s largest cancer conference. But the German and US biotech is losing its partner on the Phase 1 drug, which...
View ArticleClik here to view.
Ex-Kite leaders step in at Kyverna as CEO exits after landing year's...
Kyverna Therapeutics has reshaped its C-suite just seven months after securing one of the splashiest biotech IPOs in recent years as it rode the waves of cell therapy’s expansion into the autoimmune...
View ArticleClik here to view.
Ochre Bio CEO Jack O’Meara steps down, outlines plans for next startup
Jack O’Meara announced on LinkedIn Monday that he is stepping down from the CEO post at Ochre Bio, the liver disease startup he co-founded. In an interview with Endpoints News, he teased plans for a...
View Article